Alessandro Gronchi, MD of the National Cancer Institute, Milan, Italy gives a press brief about the results of an interim analysis of a prospective clinical trial on full-dose neoadjuvant anthracycline plus ifosfamide chemotherapy in localized high-risk soft tissue sarcomas (STS) (NCT01710176). Dr Gronchi explains that sarcoma is a rare disease and affects young adults more than elderly people. Adjuvant chemotherapy is debated in STS and its benefit not uniformly accepted. He explains the rationale of the trial comparing conventional chemotherapy versus histology-tailored chemotherapy. Then he presents the results. This is a negative trial; results shows the presence a difference in relapse-free survival (RFS) and overall survival (OS) at 3 years in favor of standard chemotherapy.
Recorded at the 2016 annual meeting of the European Society of Medical Oncology (ESMO), held in Copenhagen, Denmark.